Literature DB >> 8395789

Potent inhibition of Epstein-Barr virus by phosphorothioate oligodeoxynucleotides without sequence specification.

G Q Yao1, S Grill, W Egan, Y C Cheng.   

Abstract

We found that 28-mer phosphorothioate oligodeoxynucleotides (S-oligos) with and without sequence specificity complementary to Epstein-Barr virus (EBV) genes are potent inhibitors of EBV replication in cell culture. The decrease in the amount of EBV DNA, the activity of intracellular viral DNA polymerase, and virus production were dose dependent, with a 90% inhibitory dose of approximately 0.5 microM. No inhibition of cell growth was observed with the S-oligos at concentrations up to 20 microM. The mechanism of action appears to be the inhibition of EBV DNA synthesis. The reversibility of anti-EBV action is dependent on the dose and duration of drug exposure. S-oligos should be considered a new class of anti-EBV agents.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8395789      PMCID： PMC187987          DOI： 10.1128/AAC.37.7.1420

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  Comparative efficacy and selectivity of some nucleoside analogs against Epstein-Barr virus.

Authors:  J C Lin; M C Smith; J S Pagano
Journal:  Antimicrob Agents Chemother       Date:  1985-06       Impact factor: 5.191

2.  Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion.

Authors:  J S Greenspan; D Greenspan; E T Lennette; D I Abrams; M A Conant; V Petersen; U K Freese
Journal:  N Engl J Med       Date:  1985-12-19       Impact factor: 91.245

3.  EB viral genomes in epithelial nasopharyngeal carcinoma cells.

Authors:  H Wolf; H zur Hausen; V Becker
Journal:  Nat New Biol       Date:  1973-08-22

4.  EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx.

Authors:  H zur Hausen; H Schulte-Holthausen; G Klein; W Henle; G Henle; P Clifford; L Santesson
Journal:  Nature       Date:  1970-12-12       Impact factor: 49.962

5.  Quick-blot: selective mRNA or DNA immobilization from whole cells.

Authors:  J Bresser; J Doering; D Gillespie
Journal:  DNA       Date:  1983

6.  Effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine on serious cytomegalovirus disease in eight immunosuppressed homosexual men.

Authors:  H Masur; H C Lane; A Palestine; P D Smith; J Manischewitz; G Stevens; L Fujikawa; A M Macher; R Nussenblatt; B Baird
Journal:  Ann Intern Med       Date:  1986-01       Impact factor: 25.391

7.  Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus.

Authors:  J C Lin; M C Smith; J S Pagano
Journal:  J Virol       Date:  1984-04       Impact factor: 5.103

8.  Demonstration of a stimulatory protein for virus-specified DNA polymerase in phorbol ester-treated Epstein-Barr virus-carrying cells.

Authors:  J F Chiou; J K Li; Y C Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

9.  Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]-guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1.

Authors:  Y C Cheng; E S Huang; J C Lin; E C Mar; J S Pagano; G E Dutschman; S P Grill
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

10.  Epstein-Barr virus: inhibition of replication by three new drugs.

Authors:  J C Lin; M C Smith; Y C Cheng; J S Pagano
Journal:  Science       Date:  1983-08-05       Impact factor: 47.728
View more
  11 in total

1.  Characterization of sublines of Epstein-Barr virus producing HR-1 cells and its implication in virus propagation in culture.

Authors:  G Q Yao; C H Tsai; Y C Cheng
Journal:  Virus Genes       Date:  1995-02       Impact factor: 2.332

Review 2.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

3.  A deneddylase encoded by Epstein-Barr virus promotes viral DNA replication by regulating the activity of cullin-RING ligases.

Authors:  Stefano Gastaldello; Sebastian Hildebrand; Omid Faridani; Simone Callegari; Mia Palmkvist; Claudia Di Guglielmo; Maria G Masucci
Journal:  Nat Cell Biol       Date:  2010-02-28       Impact factor: 28.824

4.  Anti-Epstein-Barr virus (EBV) activity of beta-L-5-iododioxolane uracil is dependent on EBV thymidine kinase.

Authors:  T Kira; S P Grill; G E Dutschman; J S Lin; F Qu; Y Choi; C K Chu; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

5.  Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study.

Authors:  H B Hoh; C Hurley; C Claoue; M Viswalingham; D L Easty; P Goldschmidt; L M Collum
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

6.  Oligonucleotides designed to inhibit TLR9 block Herpes simplex virus type 1 infection at multiple steps.

Authors:  Monica M Sauter; Joshua J L Gauger; Curtis R Brandt
Journal:  Antiviral Res       Date:  2014-07-01       Impact factor: 5.970

7.  Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus.

Authors:  C K Chu; T Ma; K Shanmuganathan; C Wang; Y Xiang; S B Pai; G Q Yao; J P Sommadossi; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

Review 8.  Molecular therapeutic strategies in hepatitis B virus infection.

Authors:  W B Offensperger; H E Blum; W Gerok
Journal:  Clin Investig       Date:  1994-10

Review 9.  The antiviral prophylaxis of post-transplant lymphoproliferative disorder.

Authors:  C L Davis
Journal:  Springer Semin Immunopathol       Date:  1998

10.  Toll-like receptor 9 ligand D-type oligodeoxynucleotide D35 as a broad inhibitor for influenza A virus replication that is associated with suppression of neuraminidase activity.

Authors:  Hiroshi Yamada; Satoshi Nagase; Kazuo Takahashi; Yoshihiro Sakoda; Hiroshi Kida; Shigefumi Okamoto
Journal:  Antiviral Res       Date:  2016-02-26       Impact factor: 5.970
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.